A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA

Hilde Vroling, Anouk M. Oordt-Speets, Giordano Madeddu, Sergio Babudieri, Roberto Monarca, Eamonn O'Moore, Marije Vonk Noordegraaf-Schouten, Hans Wolff, Marialinda Montanari, Dagmar Hedrich, Lara Tavoschi*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    17 Citations (Scopus)

    Abstract

    Hepatitis C prevalence in prison populations is much higher than in the community. Effective hepatitis C treatment within this population does not only have a direct individual health benefit, but may lead to substantial community dividend. We reviewed available evidence on hepatitis C treatment in prison settings, with a focus on the European Union/European Economic Area. A systematic review of the literature (PubMed, EMBASE, Cochrane library) was performed and complemented with searches for conference abstracts and grey literature. Thirty-four publications were included reporting on the effectiveness, acceptability and economic aspects of hepatitis C virus treatment models of care to achieve treatment completion and sustained viral response in prison settings. Available evidence shows that hepatitis C treatment in prison settings is feasible and the introduction of direct-acting antivirals will most likely result in increased treatment completion and better clinical outcomes for the prison population, given the caveats of affordability and the need for increased funding for prison health, with the resulting benefits accruing mostly in the community.

    Original languageEnglish
    Pages (from-to)1406-1422
    Number of pages17
    JournalJournal of Viral Hepatitis
    Volume25
    Issue number12
    DOIs
    Publication statusPublished - Dec 2018

    Bibliographical note

    Funding Information:
    This work was supported by the European Centre for Disease Prevention and Control (framework contract number ECDC/2015/028, specific contract number ECD.5855) and is part of a wider joint undertaking with the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) to develop European guidance on the prevention of communicable diseases in the prison setting.

    Funding Information:
    Funding information This work was supported by the European Centre for Disease Prevention and Control (framework contract number ECDC/2015/028, specific contract number ECD.5855) and is part of a wider joint undertaking with the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) to develop European guidance on the prevention of communicable diseases in the prison setting. Invaluable inputs were received from the guidance ad hoc scientific panel members: Dr Viktor Mravcik (Czech Republic), Dr Fadi Meroueh (France), Dr Laurent Michel (France), Prof Heino St?ver (Germany), Dr Ruth Zimmermann (Germany), Dr Roberto Ranieri (Italy), Erica Cardoso (Portugal), Teresa Galhardo (Portugal), Dr Rui Morgado (Portugal), Dr Lucia Mihailescu (Romania), Dr Jose-Manuel Royo (Spain), Stefan Enggist (Switzerland), Prof Sharon Hutchinson (UK), Alison Hannah (Penal Reform International), Jan Malinowski (Council of Europe), Dr Lars M?ller (WHO) and Dr Ehab Salah (United Nations on Drugs and Crime). The authors would like to acknowledge the field researchers who contributed to the project: Ruth Gray, Sofia Victoria Casado Hoces, Leon Weichert and Deborah Iwanikow. The authors would like to acknowledge the ECDC library and ECDC and EMCDDA staff who contributed to the project: Dr Andrew J Amato Gauci, Dr Netta Beer, Dr Helena de Carvalho Gomes, Dr Erika Duffell and Dr Marica Ferri.

    Publisher Copyright:
    © 2018 John Wiley & Sons Ltd

    Keywords

    • Europe
    • HCV
    • prison
    • treatment

    Fingerprint

    Dive into the research topics of 'A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA'. Together they form a unique fingerprint.

    Cite this